Validation of tissue microarray technology in malignant pleural mesothelioma

S.C-H Kao; K. Lee; N.J. Armstrong; S. Clarke; J. Vardy; N. van Zandwijk; G. Reid; J. Burn; B.C. McCaughan; D.W. Henderson; S. Klebe

doi:10.1097/PAT.0b013e328342016c

Back

Validation of tissue microarray technology in malignant pleural mesothelioma

Journal article

Peer reviewed

Validation of tissue microarray technology in malignant pleural mesothelioma

S.C-H Kao, K. Lee, N.J. Armstrong, S. Clarke, J. Vardy, N. van Zandwijk, G. Reid, J. Burn, B.C. McCaughan, D.W. Henderson, …

Pathology, Vol.43(2), pp.128-132

2011

DOI: https://doi.org/10.1097/PAT.0b013e328342016c

Files and links (1)

url

Link to Published Version *Subscription may be requiredView

Abstract

AIMS: Tissue microarray (TMA) technology has been utilised for assessment of cancers including malignant pleural mesothelioma (MPM). Given the intralesional heterogeneity of MPM, it is questionable if TMAs can adequately represent MPMs. We here investigate the validity of TMAs for MPM. METHODS: TMAs were constructed from at least five cores for each of 80 archival tumours processed by two centres between 1994 and 2009. The percentage of cases correctly subtyped on TMAs compared with whole sections, in relation to the number of cores analysed, was calculated. Immunohistochemical labelling for calretinin and D2-40 was performed on TMAs and whole sections. To evaluate the validity of quantitative immunohistochemistry, percentages of positive cells were recorded and two-way analysis of variance (ANOVA) performed. RESULTS: Five cores were assessable for 91% of patients. Four cores were sufficient to reach concordance with the whole-section result in 98% of cases for calretinin and 99% for D2-40. The correlation of the quantitative scores between the whole section and TMA cores was statistically significant (D2-40, rho = 0.84, p < 2.2e-16; calretinin, rho = 0.65, p = 7.9e-11). Neither the origin nor age of the blocks affected the results. CONCLUSION: If a minimum of four cores is used, TMA is an appropriate method for immunohistochemistry in MPM.

Details

Title: Validation of tissue microarray technology in malignant pleural mesothelioma
Authors/Creators: S.C-H Kao (Author/Creator)
K. Lee (Author/Creator) - Concord Repatriation General Hospital
N.J. Armstrong (Author/Creator) - Garvan Institute of Medical Research
S. Clarke (Author/Creator) - The University of Sydney
J. Vardy (Author/Creator) - The University of Sydney
N. van Zandwijk (Author/Creator) - The University of Sydney
G. Reid (Author/Creator) - The University of Sydney
J. Burn (Author/Creator) - South Australia Pathology
B.C. McCaughan (Author/Creator) - Royal Prince Alfred Hospital
D.W. Henderson (Author/Creator) - Flinders Medical Centre
S. Klebe (Author/Creator) - Flinders Medical Centre
Publication Details: Pathology, Vol.43(2), pp.128-132
Publisher: Lippincott Williams and Wilkins
Identifiers: 991005543703107891
Copyright: © 2011 Royal College of Pathologists of Australasia
Murdoch Affiliation: Murdoch University
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

25 Record Views

28 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.297 Asbestos & Mesothelioma; 1.297.780 Asbestos-Mesothelioma Link
Web Of Science research areas: Pathology
ESI research areas: Clinical Medicine